MS-SMART

Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial

A multi-arm phase IIb randomised, double blind placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis.

 
Multiple sclerosis (MS) is a disabling and progressive neurological disease that affects approximately 100,000 people in the UK. Late or progressive MS, which affects the majority of patients typically emerges after 10-15 years of disease. There is no proven treatment for the late stage of MS and this is an urgent unmet need. MS-SMART directly addresses this need and will evaluate three drugs (fluoxetine, riluzole and amiloride), all of which have shown some promise in MS, and in particular in secondary progressive MS.
 
Chief Investigator: Professor Jeremy Chataway
Number and location of participating sites (by region/ country): 10-15 sites in England and Scotland
EudraCT number: 2012-005394-31
ISRCTN number: ISRCTN28440672 (http://www.isrctn.com/ISRCTN28440672)
 
Funder: MRC EME (Efficacy and Mechanism Evaluation Programme)
Start and End date of grant award: April 2013 to December 2018
Start and End date of reruitment: December 2014 to June 2016 (complete)
 
Current Status:  Published online January 22, 2020 https://doi.org/10.1016/S1474-4422(19)30485-
 

 

Professor Jeremy Chataway, Chief Investigator:  headline results

Dr Jeremy Chataway, Chief Investigator, presented the headline results at the international MS conference (ECTRIMS) on Friday 12 October.   A video aimed at the trial participants is available to view and you can find out the results using this link:  www.mssociety.org.uk/ms-smart-results

Website: 

Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

www.thelancet.com/neurology
 
Trial Unblinding Information: Medical professionals in circumstances where un-blinding is necessary should refer to the protocol/ MS-SMART patient card and follow instructions provided.
 
 
Contact details
Sponsor: University College London, Joint Research Office, UCL Gower Street, London WC1E 6BT. www.ucl.ac.uk/jro
Chief Investigator: Dr Jeremy Chataway, Institute of Neurology, University College London (UCL), The National Hospital for Neurology, and Neurosurgery (NHNN), University College London Hospitals, NHS Foundation Trust , Queen Square, London WC1N 3 BG. jeremy.chataway@uclh.nhs.uk
 
ECTU Involvement: Trial management, Statistics, Database, Randomisation, Unblinding
(UKCRC)

This article was published on